AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2023
Jan 6, 2023
33483_dirs_2023-01-06_74ca75ee-bce7-405e-814a-7bdce0e49de2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2023-01-04
Reporting Person: Brunn Carsten (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-04 | Common Stock | S | 27549 | $1.1337 | Disposed | 799534 | Direct |
| 2023-01-04 | Common Stock | S | 48 | $1.145 | Disposed | 799486 | Direct |
| 2023-01-05 | Common Stock | S | 13396 | $1.1293 | Disposed | 786090 | Direct |
| 2023-01-05 | Common Stock | S | 77 | $1.115 | Disposed | 786013 | Direct |
Footnotes
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
More from Cartesian Therapeutics, Inc.
Capital/Financing Update
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8